{"id":59093,"date":"2026-03-09T13:26:10","date_gmt":"2026-03-09T05:26:10","guid":{"rendered":"https:\/\/flcube.com\/?p=59093"},"modified":"2026-03-09T13:26:11","modified_gmt":"2026-03-09T05:26:11","slug":"servier-to-acquire-day-one-biopharmaceuticals-for-2-5-billion-french-pharma-expands-u-s-oncology-presence-with-adc-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59093","title":{"rendered":"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets"},"content":{"rendered":"\n<p><strong>Servier Group<\/strong> announced a <strong>definitive agreement<\/strong> to acquire <strong>Day One Biopharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/DAWN:NASDAQ\">NASDAQ: DAWN<\/a>) for <strong>$21.50 per share<\/strong>, representing a <strong>total transaction value of $2.5\u202fbillion<\/strong>. The all-cash deal, expected to <strong>close in Q2 2026<\/strong>, marks Servier&#8217;s <strong>largest U.S. biotech acquisition<\/strong> and provides immediate access to Day One&#8217;s <strong>pediatric and adult oncology pipeline<\/strong>, including the <strong>MTX-13 ADC<\/strong> licensed from <strong>Shanghai Mycos Biomedicine<\/strong> in 2024.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Servier Group (France, privately held)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)<\/td><\/tr><tr><td><strong>Purchase Price<\/strong><\/td><td>$21.50 per share (all-cash)<\/td><\/tr><tr><td><strong>Total Enterprise Value<\/strong><\/td><td>~$2.5\u202fbillion<\/td><\/tr><tr><td><strong>Premium<\/strong><\/td><td>To be determined vs. prior close<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>Q2 2026 (subject to regulatory approvals)<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>U.S. oncology expansion; ADC platform entry; pediatric expertise<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-day-one-biopharmaceuticals-profile\">Day One Biopharmaceuticals Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Focus<\/strong><\/td><td>Targeted therapies for life-threatening diseases across all ages (pediatric + adult)<\/td><\/tr><tr><td><strong>Lead Programs<\/strong><\/td><td>Tovorafenib (RAF inhibitor \u2013 pediatric low-grade glioma); pimasertib (MEK inhibitor)<\/td><\/tr><tr><td><strong>ADC Asset<\/strong><\/td><td><strong>MTX-13<\/strong> \u2013 antibody drug conjugate licensed from Shanghai Mycos Biomedicine (2024)<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Global rights to MTX-13; biologics development infrastructure<\/td><\/tr><tr><td><strong>NASDAQ Listing<\/strong><\/td><td>DAWN (IPO 2021)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>MTX-13 ADC Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Origin:<\/strong> Licensed from Shanghai Mycos Biomedicine (China-based ADC platform company)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Targeted delivery of cytotoxic payload; indication expansion potential<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Day One&#8217;s <strong>first biologic asset<\/strong>; positions acquirer in high-growth ADC modality<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-servier-portfolio-fit\">Strategic Rationale &amp; Servier Portfolio Fit<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Servier Objective<\/th><th>Day One Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. Market Presence<\/strong><\/td><td>Established South San Francisco operations; U.S. commercial infrastructure<\/td><\/tr><tr><td><strong>Oncology Pipeline<\/strong><\/td><td>Phase III-ready pediatric brain tumor program; targeted therapy expertise<\/td><\/tr><tr><td><strong>ADC Platform<\/strong><\/td><td>MTX-13 provides entry into antibody drug conjugates \u2013 fastest-growing oncology modality<\/td><\/tr><tr><td><strong>Pediatric Focus<\/strong><\/td><td>Day One&#8217;s age-agnostic development model aligns with Servier&#8217;s patient-centric approach<\/td><\/tr><tr><td><strong>Geographic Diversification<\/strong><\/td><td>Reduces European revenue concentration; balances ex-U.S. exposure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-impact\">Deal Structure &amp; Financial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Consideration<\/strong><\/td><td>100% cash<\/td><\/tr><tr><td><strong>Financing<\/strong><\/td><td>Servier private capital (no debt disclosed)<\/td><\/tr><tr><td><strong>Synergies<\/strong><\/td><td>R&amp;D integration; U.S. commercial platform leverage<\/td><\/tr><tr><td><strong>Accretion<\/strong><\/td><td>Transaction expected to be dilutive near-term; accretive by 2028-2029 pending pipeline approvals<\/td><\/tr><tr><td><strong>China Connection<\/strong><\/td><td>MTX-13 Mycos relationship provides Servier potential Asia-Pacific ADC sourcing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-dynamics\">Market Context &amp; Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>ADC M&amp;A Trend<\/strong><\/td><td>2024-2026 surge in ADC acquisitions (Pfizer\/Seagen, J&amp;J\/Ambrx); Servier secures platform at $2.5B valuation<\/td><\/tr><tr><td><strong>Pediatric Oncology<\/strong><\/td><td>Underserved market with regulatory incentives (PRV, label extensions); Day One&#8217;s tovorafenib PDUFA 2024<\/td><\/tr><tr><td><strong>French Pharma Consolidation<\/strong><\/td><td>Servier follows Sanofi, Ipsen in U.S. biotech M&amp;A; maintains independence via private ownership<\/td><\/tr><tr><td><strong>China Biotech Link<\/strong><\/td><td>MTX-13 license demonstrates Chinese ADC platform global value; Mycos may see partnership interest<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-integration-priorities\">Forward-Looking Integration Priorities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2026 Close:<\/strong> Regulatory approvals (Hart-Scott-Rodino, foreign investment reviews)<\/li>\n\n\n\n<li><strong>Pipeline Acceleration:<\/strong> Tovorafenib commercial launch (if approved); MTX-13 IND-enabling studies<\/li>\n\n\n\n<li><strong>Platform Expansion:<\/strong> Leverage Mycos relationship for additional ADC pipeline assets<\/li>\n\n\n\n<li><strong>Geographic Scale:<\/strong> Servier&#8217;s 150-country footprint enables global Day One asset distribution<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction closing, pipeline development, and strategic integration for the Servier-Day One acquisition. Actual results may differ due to regulatory approval delays, integration challenges, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[649,1336,1496],"class_list":["post-59093","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-day-one-biopharmaceuticals","tag-nasdaq-dawn","tag-servier-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share, representing a total transaction value of $2.5\u202fbillion. The all-cash deal, expected to close in Q2 2026, marks Servier&#039;s largest U.S. biotech acquisition and provides immediate access to Day One&#039;s pediatric and adult oncology pipeline, including the MTX-13 ADC licensed from Shanghai Mycos Biomedicine in 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59093\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets\" \/>\n<meta property=\"og:description\" content=\"Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share, representing a total transaction value of $2.5\u202fbillion. The all-cash deal, expected to close in Q2 2026, marks Servier&#039;s largest U.S. biotech acquisition and provides immediate access to Day One&#039;s pediatric and adult oncology pipeline, including the MTX-13 ADC licensed from Shanghai Mycos Biomedicine in 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59093\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T05:26:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T05:26:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59093#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59093\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets\",\"datePublished\":\"2026-03-09T05:26:10+00:00\",\"dateModified\":\"2026-03-09T05:26:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59093\"},\"wordCount\":503,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Day One Biopharmaceuticals\",\"NASDAQ: DAWN\",\"Servier Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59093#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59093\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59093\",\"name\":\"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-09T05:26:10+00:00\",\"dateModified\":\"2026-03-09T05:26:11+00:00\",\"description\":\"Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share, representing a total transaction value of $2.5\u202fbillion. The all-cash deal, expected to close in Q2 2026, marks Servier's largest U.S. biotech acquisition and provides immediate access to Day One's pediatric and adult oncology pipeline, including the MTX-13 ADC licensed from Shanghai Mycos Biomedicine in 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59093#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59093\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59093#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets - Insight, China&#039;s Pharmaceutical Industry","description":"Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share, representing a total transaction value of $2.5\u202fbillion. The all-cash deal, expected to close in Q2 2026, marks Servier's largest U.S. biotech acquisition and provides immediate access to Day One's pediatric and adult oncology pipeline, including the MTX-13 ADC licensed from Shanghai Mycos Biomedicine in 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59093","og_locale":"en_US","og_type":"article","og_title":"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets","og_description":"Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share, representing a total transaction value of $2.5\u202fbillion. The all-cash deal, expected to close in Q2 2026, marks Servier's largest U.S. biotech acquisition and provides immediate access to Day One's pediatric and adult oncology pipeline, including the MTX-13 ADC licensed from Shanghai Mycos Biomedicine in 2024.","og_url":"https:\/\/flcube.com\/?p=59093","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-09T05:26:10+00:00","article_modified_time":"2026-03-09T05:26:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59093#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59093"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets","datePublished":"2026-03-09T05:26:10+00:00","dateModified":"2026-03-09T05:26:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59093"},"wordCount":503,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Day One Biopharmaceuticals","NASDAQ: DAWN","Servier Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59093#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59093","url":"https:\/\/flcube.com\/?p=59093","name":"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-09T05:26:10+00:00","dateModified":"2026-03-09T05:26:11+00:00","description":"Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share, representing a total transaction value of $2.5\u202fbillion. The all-cash deal, expected to close in Q2 2026, marks Servier's largest U.S. biotech acquisition and provides immediate access to Day One's pediatric and adult oncology pipeline, including the MTX-13 ADC licensed from Shanghai Mycos Biomedicine in 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59093#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59093"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59093#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Servier to Acquire Day One Biopharmaceuticals for $2.5\u202fBillion \u2013 French Pharma Expands U.S. Oncology Presence with ADC Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59093"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59093\/revisions"}],"predecessor-version":[{"id":59095,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59093\/revisions\/59095"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}